Terms: = Prostate cancer AND PIM1, PIM, 5292, ENSG00000137193, P11309 AND Treatment
41 results:
1. Tailored horseshoe-shaped nicotinonitrile scaffold as dual promising c-Met and pim-1 inhibitors: Design, synthesis, SAR and in silico study.
Mohamady S; Khalil AF; Naguib BH; Nafie MS; Tawfik HO; Shaldam MA
Bioorg Chem; 2024 Feb; 143():106988. PubMed ID: 37995644
[TBL] [Abstract] [Full Text] [Related]
2. pim1 phosphorylates ABI2 to enhance actin dynamics and promote tumor invasion.
Jensen CC; Clements AN; Liou H; Ball LE; Bethard JR; Langlais PR; Toth RK; Chauhan SS; Casillas AL; Daulat SR; Kraft AS; Cress AE; Miranti CK; Mouneimne G; Rogers GC; Warfel NA
J Cell Biol; 2023 Jun; 222(6):. PubMed ID: 37042842
[TBL] [Abstract] [Full Text] [Related]
3. Discovery of pim-1 kinase inhibitors based on the 2,5-disubstituted 1,3,4-oxadiazole scaffold against prostate cancer: Design, synthesis, in vitro and in vivo cytotoxicity investigation.
Castanet AS; Nafie MS; Said SA; Arafa RK
Eur J Med Chem; 2023 Mar; 250():115220. PubMed ID: 36848846
[TBL] [Abstract] [Full Text] [Related]
4. Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors.
Savill KMZ; Lee BB; Oeh J; Lin J; Lin E; Chung WJ; Young A; Chen W; Miś M; Mesh K; Eastham J; Gnad F; Jiang Z; Stawiski EW; Haley B; Daemen A; Wang X; Koeppen H; Modrusan Z; Martin SE; Sampath D; Lin K
Nat Commun; 2022 Apr; 13(1):2057. PubMed ID: 35440108
[TBL] [Abstract] [Full Text] [Related]
5. Co-targeting pim and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.
Luszczak S; Simpson BS; Stopka-Farooqui U; Sathyadevan VK; Echeverria LMC; Kumar C; Costa H; Haider A; Freeman A; Jameson C; Ratynska M; Ben-Salha I; Sridhar A; Shaw G; Kelly JD; Pye H; Gately KA; Whitaker HC; Heavey S
Sci Rep; 2020 Sep; 10(1):14380. PubMed ID: 32873828
[TBL] [Abstract] [Full Text] [Related]
6. Signalling molecular recognition nanocavities with multiple functional groups prepared by molecular imprinting and sequential post-imprinting modifications for prostate cancer biomarker glycoprotein detection.
Saeki T; Takano E; Sunayama H; Kamon Y; Horikawa R; Kitayama Y; Takeuchi T
J Mater Chem B; 2020 Sep; 8(35):7987-7993. PubMed ID: 32760956
[TBL] [Abstract] [Full Text] [Related]
7. pim kinase inhibition: co-targeted therapeutic approaches in prostate cancer.
Luszczak S; Kumar C; Sathyadevan VK; Simpson BS; Gately KA; Whitaker HC; Heavey S
Signal Transduct Target Ther; 2020 Jan; 5(1):7. PubMed ID: 32296034
[TBL] [Abstract] [Full Text] [Related]
8. pim protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth.
Singh N; Padi SKR; Bearss JJ; Pandey R; Okumura K; Beltran H; Song JH; Kraft AS; Olive V
Mol Oncol; 2020 May; 14(5):974-990. PubMed ID: 32146726
[TBL] [Abstract] [Full Text] [Related]
9. Prevalence and factors associated with potentially inappropriate medication use in older medicare beneficiaries with cancer.
Feng X; Higa GM; Safarudin F; Sambamoorthi U; Chang J
Res Social Adm Pharm; 2020 Oct; 16(10):1459-1471. PubMed ID: 31926877
[TBL] [Abstract] [Full Text] [Related]
10. Potentially inappropriate medication use and associated healthcare utilization and costs among older adults with colorectal, breast, and prostate cancers.
Feng X; Higa GM; Safarudin F; Sambamoorthi U; Tan X
J Geriatr Oncol; 2019 Sep; 10(5):698-704. PubMed ID: 30772191
[TBL] [Abstract] [Full Text] [Related]
11. Single-centre Experience of Use of Radium 223 with Clinical Outcomes Based on Number of Cycles and Bone Marrow Toxicity.
Dadhania S; Alonzi R; Douglas S; Gogbashian A; Hughes R; Dalili D; Vasdev N; Adshead J; Lane T; Westbury C; Anyamene N; Ostler P; Hoskin P; Sharma A
Anticancer Res; 2018 Sep; 38(9):5423-5427. PubMed ID: 30194198
[TBL] [Abstract] [Full Text] [Related]
12. Patient-derived Models of Abiraterone- and Enzalutamide-resistant prostate cancer Reveal Sensitivity to Ribosome-directed Therapy.
Lawrence MG; Obinata D; Sandhu S; Selth LA; Wong SQ; Porter LH; Lister N; Pook D; Pezaro CJ; Goode DL; Rebello RJ; Clark AK; Papargiris M; Van Gramberg J; Hanson AR; Banks P; Wang H; Niranjan B; Keerthikumar S; Hedwards S; Huglo A; Yang R; Henzler C; Li Y; Lopez-Campos F; Castro E; Toivanen R; Azad A; Bolton D; Goad J; Grummet J; Harewood L; Kourambas J; Lawrentschuk N; Moon D; Murphy DG; Sengupta S; Snow R; Thorne H; Mitchell C; Pedersen J; Clouston D; Norden S; Ryan A; Dehm SM; Tilley WD; Pearson RB; Hannan RD; Frydenberg M; Furic L; Taylor RA; Risbridger GP
Eur Urol; 2018 Nov; 74(5):562-572. PubMed ID: 30049486
[TBL] [Abstract] [Full Text] [Related]
13. Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers.
Cortes J; Tamura K; DeAngelo DJ; de Bono J; Lorente D; Minden M; Uy GL; Kantarjian H; Chen LS; Gandhi V; Godin R; Keating K; McEachern K; Vishwanathan K; Pease JE; Dean E
Br J Cancer; 2018 May; 118(11):1425-1433. PubMed ID: 29765150
[TBL] [Abstract] [Full Text] [Related]
14. Deoxynucleosides with benzimidazoles as aglycone moiety are potent anticancer agents.
Koronkiewicz M; Chilmonczyk Z; Kazimerczuk Z; Orzeszko A
Eur J Pharmacol; 2018 Feb; 820():146-155. PubMed ID: 29246854
[TBL] [Abstract] [Full Text] [Related]
15. Hypoxia-Inducible pim Kinase Expression Promotes Resistance to Antiangiogenic Agents.
Casillas AL; Toth RK; Sainz AG; Singh N; Desai AA; Kraft AS; Warfel NA
Clin Cancer Res; 2018 Jan; 24(1):169-180. PubMed ID: 29084916
[No Abstract] [Full Text] [Related]
16. The Dual Inhibition of RNA Pol I Transcription and pim Kinase as a New Therapeutic Approach to Treat Advanced prostate cancer.
Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
[TBL] [Abstract] [Full Text] [Related]
17. pim Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.
Warfel NA; Sainz AG; Song JH; Kraft AS
Mol Cancer Ther; 2016 Jul; 15(7):1637-47. PubMed ID: 27196781
[TBL] [Abstract] [Full Text] [Related]
18. pim kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
[TBL] [Abstract] [Full Text] [Related]
19. A small-molecule inhibitor of pim kinases as a potential treatment for urothelial carcinomas.
Foulks JM; Carpenter KJ; Luo B; Xu Y; Senina A; Nix R; Chan A; Clifford A; Wilkes M; Vollmer D; Brenning B; Merx S; Lai S; McCullar MV; Ho KK; Albertson DJ; Call LT; Bearss JJ; Tripp S; Liu T; Stephens BJ; Mollard A; Warner SL; Bearss DJ; Kanner SB
Neoplasia; 2014 May; 16(5):403-12. PubMed ID: 24953177
[TBL] [Abstract] [Full Text] [Related]
20. RNAi screen identifies a synthetic lethal interaction between pim1 overexpression and PLK1 inhibition.
van der Meer R; Song HY; Park SH; Abdulkadir SA; Roh M
Clin Cancer Res; 2014 Jun; 20(12):3211-21. PubMed ID: 24771642
[TBL] [Abstract] [Full Text] [Related]
[Next]
